| Biomarker ID | 359 |
| PMID | 18559597 |
| Year | 2008 |
| Biomarker | TGF-β1 + sIL-6R + IL-6 + VCAM-1 + VEGF + endoglin + uPA |
| Biomarker Basis | Concentration Based (ng/ml+pg/ml (VEGF)) |
| Biomolecule | Protein |
| Source | Plasma |
| Subjects | Humans |
| Regulation | Increased with Biochemical Recurrence |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include(VGEFA):-S1P/S1P3 pathway, VEGFR1 pathway,Heart development,Actions of nitric oxide in the heart,Fibroblast growth factor 1 |
| Experiment | Biochemical Recurrence Vs no Recurrence in 5 years |
| Type of Biomarker | Prognostic |
| Cohort | 423 patients treated with radical prostatectomy and bilateral lymphadenectomy for clinically localized prostatic adenocarcinoma were chosen. |
| Senstivity | NA |
| Specificity | NA |
| AUC | Multivariate: Concordance Index: 86.6 |
| Accuracy | NA |
| Level Of Significance | NA |
| Method Used | enzyme immunoassays |
| Clinical | No |
| Remarks | Multivariate Analysis. Biochemical recurrence was defined as a sustained elevation, on two or more occasions, of serum total prostate-specific antigen >0.2 ng/mL |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | TGFB1, IL6, IL6, VCAM1, VEGFA, ENG, PLAU |